Cirrhotic Cardiomyopathy and Cardiac Dysfunction in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease

What this Trial Is About

Researchers are investigating the connection between non-alcoholic fatty liver disease (NAFLD), also called metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiac dysfunction. Conditions like cirrhotic cardiomyopathy, coronary artery disease, and heart failure are being studied due to their links with NAFLD. The study aims to develop a model for cardiac dysfunction in patients with NAFLD, as heart problems are a significant cause of mortality in this group. Participants will undergo various non-invasive tests such as APRI, FIB-4, FAST scan, and vibration-controlled transient elastography (Fibroscan) to evaluate liver status. Liver biopsy may be performed if clinically indicated. Echocardiographic assessments using M mode, cross-sectional, and Doppler techniques will examine heart structure and function to detect abnormalities. Diagnosis of NAFLD will be based on medical history, physical exams, lab tests, imaging, and liver biopsy when available. Throughout the study, researchers will collect data on heart function and liver disease severity, including echocardiographic measurements and myocardial and perfusion abnormalities. The main goal is to determine how common cardiac dysfunction is in NAFLD patients. Additional outcomes include tracking mortality rates and cardiac event-related deaths up to 12 months after enrollment. Participants will be monitored using non-invasive assessments and clinical evaluations during the study period.

Cardiac Dysfunction in Patients with Fatty Liver Disease